Rallybio Corp
About Rallybio Corp
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $858.0K
- Net income
- -$9.0M
- Total assets
- $62.3M
- Market cap
- $92.5M
- Operating margin
- -3853.6%
- Net margin
- -1046.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $858.0K
- Operating expenses
- $33.9M
- Operating income
- -$33.1M
- Income tax
- $0
- Net income
- -$9.0M
- EPS (basic)
- $-1.59
- EPS (diluted)
- $-1.59
Balance sheet
- Total assets
- $62.3M
- Current assets
- $61.3M
- Total liabilities
- $4.3M
- Current liabilities
- $4.2M
- Shareholders’ equity
- $58.0M
Cash flow
- Operating cash flow
- -$29.8M
- Investing cash flow
- $47.3M
- Financing cash flow
- $16.0K
- Net cash flow
- $17.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $92.5M
- EPS (diluted)
- $-1.59
- Shares outstanding
- 5.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 29, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $9.0M in FY2025.
- Trading 6% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Rallybio Corp.
Write a review
News about Rallybio Corp
News & sentiment via Polygon.io
